Orphan drugs after GSAV

Schönermark, P. 
Orphan Drugs nach GSAV - New basic conditions for approval and reimbursement
Healthcare Marketing Nr. 7 /2019, S. 30-32, New Business Verlag

The law for more safety in the provision of medicinal products (Gesetz für mehr Sicherheit in der Arzneimittelversorgung/ GSAV) passed the German Federal Council without discussion or amendment on the 28th of June 2019. The Federal Ministry of Health and its federal minister Jens Spahn had passed the bill through the legislature within only seven months. As soon as the law comes into force, essential framework conditions for market access and the reimbursement of drugs for the treatment of rare diseases, so-called orphan drugs, will change in Germany.

The article includes a summary of the decisive points of the GSAV and a discussion of its strategic importance for the pricing and reimbursement of orphan drugs. The full text of this publication can be found in Healthcare Marketing No. 7 /2019: "Orphan Drugs - New framework conditions for approval and reimbursement".

Get in touch

Ihr Ansprechpartner Univ.-Prof. Dr. med. Matthias P. Schönermark
Univ.-Prof. Dr. med. Matthias P. Schönermark
Gründer und Geschäftsführer
Fon: +49 511 64 68 14 0 – 0
Fax: +49 511 64 68 14 18
to the top
Important information about the corona virus

Dear business associates,
despite the pandemic crisis, SKC is up and running. Due to significant investments in digital and agile technology and processes in the recent years, we are offering our comprehensive professional services in an unrestricted way.

The office in Hannover is manned and accessible through all established channels.

Stay healthy!
The SKC-Team